



NDA 016885/S-029

## SUPPLEMENT APPROVAL

HRA Pharma Rare Diseases  
Attention: Richard E. Lowenthal, MS, MBA  
Appointed US Agent for HRA Pharma Rare Diseases  
c/o Pacific Link Consulting  
8195 Run of the Knolls Court  
San Diego, CA 92127

Dear Mr. Lowenthal:

Please refer to your supplemental new drug application (sNDA) dated and received May 6, 2021, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Lysodren (mitotane) tablets.

This “Changes Being Effectuated” sNDA provides for revisions to the Full Prescribing Information (FPI) Section 6 ADVERSE REACTIONS, to add the adverse reaction of hypogonadism(in males); and to Section 7 DRUG INTERACTIONS subsection 7.1 Certain CYP3A Substrates, to add information regarding concomitant use of Lysodren (mitotane) with certain CYP3A substrates. In addition, Highlights of Prescribing Information was updated to reflect revisions made to the FPI.

### **APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

### **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.<sup>1</sup> Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information), with the addition of any labeling changes in pending “Changes Being Effectuated” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

---

<sup>1</sup> <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.<sup>2</sup>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

---

<sup>2</sup> We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

If you have any questions, call Idara Udoh, Chief, Project Management Staff, at 301-796-3074.

Sincerely,

*{See appended electronic signature page}*

Abhilasha Nair, M.D.  
Associate Director for Safety (acting)  
Office of Oncologic Diseases  
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
  - Prescribing Information

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

ABHILASHA NAIR  
06/15/2021 01:53:08 PM